Amylin Pharmaceuticals Highlights 2009 Value Creation Opp...( Product and Operational Targets Prese...)

Product and Operational Targets Presented At JPMorgan Healthcare Conference

SAN FRANCISCO, Jan. 12 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced product and operational targets for 2009 that provide the opportunity to transform diabetes and obesity treatment and position the Company to be cash flow positive by the end of 2010. The news was presented by Daniel M. Bradbury, president and chief executive officer, at the JPMorgan Healthcare Conference in San Francisco, CA.

"The epidemics of diabetes and obesity, which synergistically contribute to cardiovascular disease, are the major health crises of our lifetime," said Bradbury. "The significant unmet need in the diabetes and obesity markets provides an opportunity for Amylin's first-in-class therapies to create tremendous benefit. We look to 2009 to further improve health outcomes for patients, physicians and payors, and to increase shareholder value."

2009 CORPORATE TARGETS

During his remarks, Bradbury highlighted the key 2009 value creation opportunities for Amylin. These targets include the following:

• Gain approval for an expanded indication of BYETTA as a monotherapy, finalize label updates and return the product to growth
• Leverage knowledge gained from BYETTA to submit the New Drug Application (NDA) for exenatide once weekly and execute the DURATION head-to-head clinical program designed to show comparative superiority
• Continue growing SYMLIN revenue
• Complete obesity clinical trials with amylin/leptin analogs and finalize obesity development and funding strategy
• Improve operating results and make significant progress toward achieving positive operating cash flow by the end of 2010